Coming October 29: SITC releases its late-breaking abstract titles. We’ll add their presenting authors’ institutions to this guide once they’re out.

Hanx Biopharmaceuticals at SITC 2026

Nov 4–8, 2026 Phoenix, AZ ~6k attendees Website

Hanx Biopharmaceuticals brings 3 presentations to SITC 2026 in Phoenix. Its program centres on OX40-targeted antibodies, for cancer and for depleting T cells in autoimmune disease. It also proposes OX40 as a possible cancer-driving gene in certain T-cell lymphomas.

Organization	SITC 2026 Attendance
Hanx Biopharmaceuticals Wuhan, China
hanxbio.com Biotech Biopharmaceutical company developing antibody-based cancer therapies, including OX40-targeted candidates.	Poster Fri Nov 6 12:15–1:45pm 5:30–7pm HX111, a FIC OX40-mAb-VC-MMAE for oncology, is exploited for POC investigation as a potential T-cell depleting candidate for autoimmunity Exhibition Halls 4-6 · Poster 871 New agents Poster Sat Nov 7 12:30–1:30pm 6:40–8:10pm HX011-dFc, a novel OX40-mAb with silenced Fc, as a potential T-cell depletory candidate for the treatment of autoimmune diseases Exhibition Halls 4-6 · Poster 872 New agents Poster Sat Nov 7 12:30–1:30pm 6:40–8:10pm OX40 could potentially be a novel causal oncogenic driver for certain T-cell lymphoma Exhibition Halls 4-6 · Poster 1168 Tumor biology

Organization

SITC 2026 Attendance

Hanx Biopharmaceuticals

Wuhan, China

hanxbio.com

Biotech

Biopharmaceutical company developing antibody-based cancer therapies, including OX40-targeted candidates.

Poster

Fri Nov 6
12:15–1:45pm
5:30–7pm

HX111, a FIC OX40-mAb-VC-MMAE for oncology, is exploited for POC investigation as a potential T-cell depleting candidate for autoimmunity

Exhibition Halls 4-6 · Poster 871

New agents